Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer

IF 4.9 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology Pub Date : 2024-11-06 DOI:10.1016/j.radonc.2024.110618

Jarey H. Wang , Matthew P. Deek , Adrianna A. Mendes , Yang Song , Amol Shetty , Soha Bazyar , Kim Van der Eecken , Emmalyn Chen , Timothy N. Showalter , Trevor J. Royce , Tamara Todorovic , Huei-Chung Huang , Scott A. Houck , Rikiya Yamashita , Ana P. Kiess , Daniel Y. Song , Tamara Lotan , Theodore DeWeese , Luigi Marchionni , Lei Ren , Piet Ost

{"title":"Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer","authors":"Jarey H. Wang , Matthew P. Deek , Adrianna A. Mendes , Yang Song , Amol Shetty , Soha Bazyar , Kim Van der Eecken , Emmalyn Chen , Timothy N. Showalter , Trevor J. Royce , Tamara Todorovic , Huei-Chung Huang , Scott A. Houck , Rikiya Yamashita , Ana P. Kiess , Daniel Y. Song , Tamara Lotan , Theodore DeWeese , Luigi Marchionni , Lei Ren , Piet Ost","doi":"10.1016/j.radonc.2024.110618","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>There is a need for clinically actionable prognostic and predictive tools to guide the management of oligometastatic castration-sensitive prostate cancer (omCSPC).</div></div><div><h3>Methods</h3><div>This is a multicenter retrospective study to assess the prognostic and predictive performance of a multimodal artificial intelligence biomarker (MMAI; the ArteraAI Prostate Test) in men with omCSPC (n = 222). The cohort also included 51 patients from the STOMP and ORIOLE phase 2 clinical trials which randomized patients to observation versus metastasis-directed therapy (MDT). MMAI scores were computed from digitized histopathology slides and clinical variables. Overall survival (OS) and time to castration-resistant prostate cancer (TTCRPC) were assessed for the entire cohort from time of diagnosis. Metastasis free survival (MFS) was assessed for the trial cohort from time of randomization.</div></div><div><h3>Results</h3><div>In the overall cohort, patients with a high MMAI score had significantly worse OS (HR = 6.46, 95 % CI = 1.44–28.9; p = 0.01) and shorter TTCRPC (HR = 2.07, 95 % CI = 1.15–3.72; p = 0.015). In a multivariable Cox model, MMAI score remained the only variable significantly associated with OS (HR = 6.51, 95 % CI = 1.32–32.2; p = 0.02). In the subset of patients randomized in the STOMP and ORIOLE trials, high MMAI score corresponded to improved MFS with MDT (p = 0.039) compared to patients with a low score, with p<sub>interaction</sub> = 0.04.</div></div><div><h3>Conclusion</h3><div>The ArteraAI MMAI biomarker is prognostic for OS and TTCRPC among patients with omCSPC and may predict for response to MDT. Further work is needed to validate the MMAI biomarker in a broader mCSPC cohort.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"202 ","pages":"Article 110618"},"PeriodicalIF":4.9000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiotherapy and Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0167814024042804","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

There is a need for clinically actionable prognostic and predictive tools to guide the management of oligometastatic castration-sensitive prostate cancer (omCSPC).

Methods

This is a multicenter retrospective study to assess the prognostic and predictive performance of a multimodal artificial intelligence biomarker (MMAI; the ArteraAI Prostate Test) in men with omCSPC (n = 222). The cohort also included 51 patients from the STOMP and ORIOLE phase 2 clinical trials which randomized patients to observation versus metastasis-directed therapy (MDT). MMAI scores were computed from digitized histopathology slides and clinical variables. Overall survival (OS) and time to castration-resistant prostate cancer (TTCRPC) were assessed for the entire cohort from time of diagnosis. Metastasis free survival (MFS) was assessed for the trial cohort from time of randomization.

Results

In the overall cohort, patients with a high MMAI score had significantly worse OS (HR = 6.46, 95 % CI = 1.44–28.9; p = 0.01) and shorter TTCRPC (HR = 2.07, 95 % CI = 1.15–3.72; p = 0.015). In a multivariable Cox model, MMAI score remained the only variable significantly associated with OS (HR = 6.51, 95 % CI = 1.32–32.2; p = 0.02). In the subset of patients randomized in the STOMP and ORIOLE trials, high MMAI score corresponded to improved MFS with MDT (p = 0.039) compared to patients with a low score, with p_interaction = 0.04.

Conclusion

The ArteraAI MMAI biomarker is prognostic for OS and TTCRPC among patients with omCSPC and may predict for response to MDT. Further work is needed to validate the MMAI biomarker in a broader mCSPC cohort.

查看原文本刊更多论文

验证基于人工智能的寡转移性阉割敏感性前列腺癌患者预后生物标志物。

背景：临床上需要可操作的预后和预测工具来指导治疗少转移性阉割敏感性前列腺癌（omCSPC）：临床上需要可操作的预后和预测工具来指导寡转移性阉割敏感性前列腺癌（omCSPC）的治疗：这是一项多中心回顾性研究，旨在评估多模态人工智能生物标志物（MMAI；ArteraAI前列腺测试）对omCSPC男性患者（n = 222）的预后和预测性能。该队列还包括来自STOMP和ORIOLE 2期临床试验的51名患者，这些试验将患者随机分为观察组和转移导向疗法（MDT）组。根据数字化组织病理学切片和临床变量计算出MMAI评分。评估了整个组群从确诊开始的总生存期（OS）和发生耐阉割前列腺癌的时间（TTCRPC）。对试验队列的无转移生存期（MFS）进行了评估，时间从随机化开始：结果：在整个队列中，MMAI评分高的患者OS明显较差（HR = 6.46，95 % CI = 1.44-28.9；p = 0.01），TTCRPC明显较短（HR = 2.07，95 % CI = 1.15-3.72；p = 0.015）。在多变量 Cox 模型中，MMAI 评分仍是与 OS 显著相关的唯一变量（HR = 6.51，95 % CI = 1.32-32.2；p = 0.02）。在 STOMP 和 ORIOLE 试验的随机患者子集中，与低分患者相比，MMAI 高分患者在接受 MDT 治疗后的 MFS 有所改善（p = 0.039），pinteraction = 0.04：ArteraAI MMAI生物标志物可预测omCSPC患者的OS和TTCRPC，并可预测对MDT的反应。还需要在更广泛的 mCSPC 群体中进一步验证 MMAI 生物标记物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Radiotherapy and Oncology 医学-核医学

CiteScore

10.30

自引率

10.50%

发文量

2445

审稿时长

45 days

期刊介绍： Radiotherapy and Oncology publishes papers describing original research as well as review articles. It covers areas of interest relating to radiation oncology. This includes: clinical radiotherapy, combined modality treatment, translational studies, epidemiological outcomes, imaging, dosimetry, and radiation therapy planning, experimental work in radiobiology, chemobiology, hyperthermia and tumour biology, as well as data science in radiation oncology and physics aspects relevant to oncology.Papers on more general aspects of interest to the radiation oncologist including chemotherapy, surgery and immunology are also published.